Brahmi vs Shankhpushpi: Memory & Anxiety

If you shop in the Ayurvedic aisle, these two names collide constantly. Brahmi (most commonly Bacopa monnieri) and shankhpushpi (Convolvulus pluricaulis in the official Ayurvedic Pharmacopoeia of India; regionally also Evolvulus alsinoides and Clitoria ternatea [1]) are both classified as medhya rasayana — rejuvenatives said to support the mind. But they arrive with very different evidence: brahmi has a coherent set of randomized trials behind it; shankhpushpi has mostly tradition and open-label studies. This guide compares them head to head — botanical identity, what the trials actually show for memory and anxiety, dosage, and how to choose.

Identity First: What Are We Actually Comparing?

This is the part most comparison articles skip — and it matters, because one of these names is botanically clean and the other is a moving target.

• *Brahmi = Bacopa monnieri (classical brahmi). The commercial and research identity is stable: memory trials overwhelmingly tested standardized extracts (notably KeenMind/CDRI08, ≥55% bacosides). Note the regional wrinkle: in parts of India (particularly North India), Centella asiatica (gotu kola) is sold as "brahmi" in local tradition — though classically brahmi is Bacopa monnieri and gotu kola is mandukaparni (Ayurvedic Pharmacopoeia of India) — but the global research corpus on "brahmi" means Bacopa monnieri*.
• Shankhpushpi = botanically contested. The Ayurvedic Pharmacopoeia of India recognizes Convolvulus pluricaulis as official shankhpushpi; Evolvulus alsinoides is used in the south and Clitoria ternatea in Kerala [1]. Different commercial products may contain different species — which means trial data on one species doesn't automatically transfer to what's in your bottle. No major human randomized trial of an identified C. pluricaulis product was found in the published literature (the ADDF Cognitive Vitality dossier summarizes only small open-label studies).

Practical consequence: with brahmi you can buy a standardized extract and plausibly replicate the trials. With shankhpushpi, "what worked" is harder to pin down because the identity of the tested material — and the product on the shelf — is less certain.

Head-to-Head Comparison Table

For Memory: What the Evidence Shows

Brahmi has the evidence; shankhpushpi has the tradition. The brahmi memory trials are unusually coherent for an herb: Stough 2001 (46 healthy volunteers, 300 mg/day KeenMind for 12 weeks, improved learning rate and AVLT memory consolidation, maximal at 12 weeks), Roodenrys 2002 (76 adults aged 40–65, weight-based dosing of 300 mg/day for <90 kg / 450 mg/day for >90 kg for 12 weeks, decreased rate of forgetting of newly acquired information), Stough 2008 (107 recruited, 62 completed; 2×150 mg KeenMind for 90 days, improved spatial working memory accuracy), Calabrese 2008 (54 adults 65+, 300 mg/day for 12 weeks, improved AVLT delayed word recall and Stroop performance), with the Kongkeaw 2014 meta-analysis (9 RCTs, 518 subjects) and the Pase 2012 systematic review (6 RCTs, all 12 weeks, 300–450 mg/day) converging on ~300 mg/day of standardized extract for 12 weeks as the evidence-backed regimen [2, 3, 4, 5, 6].

For shankhpushpi, the Alzheimer's Drug Discovery Foundation's Cognitive Vitality dossier summarizes only small open-label studies — no randomized controlled trials were identified [9]. That's not proof of ineffectiveness; it's an absence of the kind of evidence brahmi has. If your goal is specifically memory support with trial backing, brahmi is the evidence-based pick.

For Anxiety & Calm: What the Evidence Shows

Here the gap narrows, but brahmi still leads. Calabrese 2008 (54 adults 65+, 300 mg/day, 12 weeks) found CESD-10 depression scores and combined state-plus-trait anxiety scores decreased over time in the bacopa group while increasing in the placebo group — the anxiety signal was already visible at the 6-week interim, while AVLT memory gains appeared only at 12 weeks [7] — and Lopresti & Smith 2025 (101 adults aged 40–70, 300 mg/day Bacumen for 12 weeks) found greater reductions in overall self-reported stress reactivity (p=0.03) plus less fatigue and stress after a cognitive task, even though cognition itself did not differ between groups [8].

Shankhpushpi's traditional use centers on calming and mental clarity — Ayurvedic reviews describe it as indicated for anxiety, restlessness/neurosis, insomnia, and mental fatigue, a medhya rasayana used to induce calm and restful sleep (chittodvega, or anxiety disorders, in Ayurvedic classification [14]). But human trial evidence for anxiolytic effects is limited to open-label work, so the calming case rests on tradition rather than RCTs.

Honest framing: neither herb is a strong anxiolytic by clinical-trial standards — that category belongs to interventions with dedicated anxiety trials (e.g., ashwagandha in the Chandrasekhar 2012 trial, which reduced perceived-stress scores by 44.0% and serum cortisol by 27.9% vs placebo, and the Salve 2019 dose-ranging RCT [13]). Between the two, shankhpushpi is the more "calming-oriented" traditional choice, while brahmi carries the stronger (still modest) trial evidence for stress reactivity.

Dosage Comparison

If you choose brahmi, dose to bacoside content, not capsule weight (300 mg at 55% ≈ 165 mg bacosides). If you choose shankhpushpi, favor products that name the species on the label — Convolvulus pluricaulis is the pharmacopoeial species — since identity is the main variable.

Safety Comparison

Both have favorable safety profiles, with different caveats:

• Brahmi: GI upset, nausea, dry mouth, fatigue in trials; animal data show raised T4 (200 mg/kg extract raised T4 ~41% in male mice, T3 unchanged — Kar et al., J Ethnopharmacol 2002 [11]; no human thyroid data exists) — discuss with your prescriber if you take thyroid medication; insufficient pregnancy data; stop 2–3 weeks before planned surgery (general herbal-medication precaution per ASA guidance).
• Shankhpushpi: animal toxicology is reassuring (C. pluricaulis no mortality to 5,000 mg/kg in acute OECD 425 testing; E. alsinoides safe to 2,000 mg/kg in acute and 28-day subacute mouse studies); Panda & Kar 2001 found the root extract suppressed T3 production by inhibiting T4-to-T3 conversion in hyperthyroid mice [10] — the same thyroid caution applies; excessive intake above ~12 g/day is flagged on precautionary grounds (that threshold comes from the site's own remedy page, not a published study); phenytoin interaction: two patients lost seizure control with reduced plasma phenytoin levels while taking shankhapushpi, and rat follow-up showed co-administration lowered phenytoin levels and antiepileptic activity — the clinical combination is not advised (Dandekar et al. 1992 [12]).

Shared caution: both interact with thyroid physiology in animal models — anyone on thyroid medication should involve their prescriber before using either.

How to Choose

• Memory support with trial backing → brahmi (standardized extract, 300 mg/day, 12 weeks).
• Traditional calming use, and you're comfortable with tradition-grade evidence → shankhpushpi (species-identified product).
• Anxiety as the primary goal → look beyond both — the trial evidence for anxiety belongs more to ashwagandha (Chandrasekhar 2012: PSS −44.0% vs 5.5% placebo, cortisol −27.9% vs 7.9% placebo [13]) than to either of these. See our ashwagandha guides.
• Combination: traditional formulations sometimes combine medhya herbs, but no published human trials of brahmi + shankhpushpi together were identified — introduce separately.

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.